Date: 2015-11-11
Type of information: Nomination
Compound:
Company: SELLAS Life Sciences (Switzerland)
Therapeutic area: Cancer - Oncology - CNS diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On November 11, 2015, SELLAS Life Sciences Group announced that it has appointed to its Scientific Advisory Board Larry W. Kwak, MD, PhD, of the City of Hope National Medical Center, and Jedd D. Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSK). Drs. Kwak and Wolchok join existing members of SELLAS’s SAB, including: David A. Scheinberg, MD, PhD, of MSK; Prof. Agamemnon A. Epenetos, MB, ChB, PhD, FRCP, of Trojantec Limited; Sattva Neelapu, MD, PhD, of the University of Texas M.D. Anderson; Prof. Dr. Gunter U. Hoglinger, MD, PhD, of the German Center for Neurodegenerative Diseases (DZNE), and Prof. Antonio Daniele, MD, PhD, of Catholic University. Larry W. Kwak, MD, PhD is Cancer Center Associate Director, Translational Research & Developmental Therapeutics for the City of Hope National Medical Center, Director of the Toni Stephenson Lymphoma Center within the Hematologic Malignancies and Stem Cell Transplantation Institute, and is endowed with the title of the Dr. Michael Friedman Professor in Translational Medicine. From 2004 to 2014, Dr. Kwak served as Chairman of the Department of Lymphoma and Myeloma and Co-Director of the Center for Cancer Immunology Research at the University of Texas, M.D. Anderson Cancer Center in Houston, Texas, where he also held the Jane and John Justin Distinguished Chair in Leukemia Research. Prior to his role at M.D. Anderson, Dr. Kwak served as Head of the Vaccine Biology Section, Experimental Transplantation and Immunology Branch, at the National Cancer Institute for 12 years. His laboratory at the NCI was credited with the bench-to-clinic development of a therapeutic cancer vaccine for B-cell malignancies. In 2010, Kwak was named to TIME Magazine’s TIME100 as one of the world’s 100 most influential people for his 20-year commitment to the science of cancer vaccines, specifically a personalized therapy for follicular lymphoma. Dr. Kwak received his medical degree from Northwestern University Medical School and earned his Ph.D. in tumor cell biology there in 1984. He also completed a residency in internal medicine and a fellowship in medical oncology at Stanford University Medical Center in California. Jedd D. Wolchok, MD, PhD is Chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center, an associate director of the Ludwig Center for Cancer Immunotherapy at MSK, an associate member of Ludwig Cancer Research, and the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation at MSK. He is also director of the CRI/Ludwig Cancer Vaccine Collaborative Trials Network, and is an associate director of the CRI Scientific Advisory Council. Further, he is the co-director of the Swim Across America laboratory at MSK, one of the foremost immunotherapy and melanoma research groups in the country. Dr. Wolchok was instrumental in the clinical development leading to the approval of ipilimumab for advanced melanoma, and he is Principal Investigator of numerous ongoing clinical trials at MSK in the area of immunotherapy. He is also Associate Professor in the Immunology and Microbial Pathogenesis Program at Weill Cornell Graduate School of Medical Sciences of Cornell University and an Associate Professor of Medicine at Weill Cornell Medical College. Dr. Wolchok received his undergraduate degree from Princeton University and his master’s, medical, and doctorate degrees from New York University. He completed his internship and residency at the New York University Medical Center/Bellevue Hospital and his fellowship at MSKCC, where he was named Chief Fellow in Medical Oncology-Hematology.
Financial terms:
Latest news:
